ClinicalTrials.gov
public full text
Public Domain
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort#1157670
- Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia#1033547
- Decision-Making in Frontotemporal Dementia: Clinical, Theoretical and Legal Implications#270123
- Factors influencing accelerated progression in behavioral variant frontotemporal dementia.#288623
- Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease#1033608
Record · ID 969236
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive